alanine has been researched along with Complications, Infectious Pregnancy in 17 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When started in pregnancy, dolutegravir-containing regimens had superior virological efficacy at delivery compared with the efavirenz, emtricitabine, and tenofovir disoproxil fumarate regimen." | 9.41 | Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 ( Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 8.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| "When started in pregnancy, dolutegravir-containing regimens had superior virological efficacy at delivery compared with the efavirenz, emtricitabine, and tenofovir disoproxil fumarate regimen." | 5.41 | Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 ( Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021) |
| "Tenofovir alafenamide (TAF) is a key component of HIV treatment, but pharmacokinetic data supporting the use of TAF during pregnancy are limited." | 4.12 | Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. ( Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 4.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| "Most (85%) women received highly active antiretroviral therapy (HAART) during pregnancy (mean duration: 31 weeks) and zidovudine during labor (93%)." | 3.72 | Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. ( Artuch, R; Fortuny, C; Jimenez, R; Muñoz-Almagro, C; Noguera, A; Pou, J; Sanchez, E; Vilaseca, MA, 2004) |
| "Data on its use in pregnancy are limited." | 1.72 | Early Administration of Remdesivir and Intensive Care Unit Admission in Hospitalized Pregnant Individuals With Coronavirus Disease 2019 (COVID-19). ( Abdelwahab, M; Cackovic, M; Colburn, N; Costantine, MM; Day, S; Eid, J; Rood, KM, 2022) |
| " Secondary assessments included maternal HBV DNA reduction at delivery, and maternal or infant adverse events during follow up." | 1.56 | Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. ( Cao, L; Chen, B; Chen, R; Ding, Y; Fan, J; Gan, W; Huang, Y; Lin, C; Liu, Y; Pan, CQ; Sheng, Q; Wang, S; Wang, Y; Zhu, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 15 (88.24) | 2.80 |
| Authors | Studies |
|---|---|
| Eid, J | 1 |
| Abdelwahab, M | 1 |
| Colburn, N | 1 |
| Day, S | 1 |
| Cackovic, M | 1 |
| Rood, KM | 1 |
| Costantine, MM | 1 |
| Brooks, KM | 2 |
| Pinilla, M | 1 |
| Stek, AM | 1 |
| Shapiro, DE | 1 |
| Barr, E | 1 |
| Febo, IL | 1 |
| Paul, ME | 1 |
| Deville, JG | 1 |
| George, K | 1 |
| Knowles, K | 1 |
| Rungruengthanakit, K | 1 |
| Browning, R | 1 |
| Chakhtoura, N | 2 |
| Capparelli, EV | 1 |
| Mirochnick, M | 2 |
| Best, BM | 1 |
| Marikawa, Y | 1 |
| Alarcon, VB | 1 |
| Eke, AC | 1 |
| Gebreyohannes, RD | 1 |
| Sheffield, JS | 2 |
| Dooley, KE | 1 |
| Naqvi, M | 2 |
| Zakowski, P | 1 |
| Glucksman, L | 1 |
| Smithson, S | 1 |
| Burwick, RM | 2 |
| Igbinosa, I | 1 |
| Miller, S | 1 |
| Bianco, K | 1 |
| Nelson, J | 1 |
| Kappagoda, S | 1 |
| Blackburn, BG | 2 |
| Grant, P | 1 |
| Subramanian, A | 1 |
| Lyell, DJ | 1 |
| El-Sayed, YY | 1 |
| Aziz, N | 1 |
| McCoy, JA | 1 |
| Short, WR | 2 |
| Srinivas, SK | 1 |
| Levine, LD | 1 |
| Hirshberg, A | 2 |
| Ding, Y | 1 |
| Cao, L | 1 |
| Zhu, L | 1 |
| Huang, Y | 1 |
| Lin, C | 1 |
| Wang, Y | 1 |
| Liu, Y | 1 |
| Sheng, Q | 1 |
| Wang, S | 1 |
| Fan, J | 1 |
| Chen, R | 1 |
| Gan, W | 1 |
| Chen, B | 1 |
| Pan, CQ | 1 |
| Yawetz, S | 1 |
| Stephenson, KE | 1 |
| Collier, AY | 1 |
| Sen, P | 1 |
| Kojic, EM | 1 |
| Suarez, JF | 1 |
| Sobieszczyk, ME | 1 |
| Marks, KM | 1 |
| Mazur, S | 1 |
| Big, C | 1 |
| Manuel, O | 1 |
| Morlin, G | 1 |
| Rose, SJ | 1 |
| Goldfarb, IT | 1 |
| DeZure, A | 1 |
| Telep, L | 1 |
| Tan, SK | 1 |
| Zhao, Y | 1 |
| Hahambis, T | 1 |
| Hindman, J | 1 |
| Chokkalingam, AP | 1 |
| Carter, C | 1 |
| Das, M | 1 |
| Osinusi, AO | 1 |
| Brainard, DM | 1 |
| Varughese, TA | 1 |
| Kovalenko, O | 1 |
| Sims, MD | 1 |
| Desai, S | 1 |
| Swamy, G | 1 |
| Zash, R | 1 |
| Khan, MSI | 1 |
| Nabeka, H | 1 |
| Akbar, SMF | 1 |
| Al Mahtab, M | 1 |
| Shimokawa, T | 1 |
| Islam, F | 1 |
| Matsuda, S | 1 |
| Zeng, QL | 1 |
| Yu, ZJ | 1 |
| Ji, F | 1 |
| Li, GM | 1 |
| Zhang, GF | 1 |
| Xu, JH | 1 |
| Chen, ZM | 1 |
| Cui, GL | 1 |
| Li, W | 1 |
| Zhang, DW | 1 |
| Li, J | 1 |
| Lv, J | 1 |
| Li, ZQ | 1 |
| Liang, HX | 1 |
| Sun, CY | 1 |
| Pan, YJ | 1 |
| Liu, YM | 1 |
| Wang, FS | 1 |
| Lampejo, T | 1 |
| Lockman, S | 1 |
| Brummel, SS | 1 |
| Ziemba, L | 1 |
| Stranix-Chibanda, L | 1 |
| McCarthy, K | 1 |
| Coletti, A | 1 |
| Jean-Philippe, P | 1 |
| Johnston, B | 1 |
| Krotje, C | 1 |
| Fairlie, L | 1 |
| Hoffman, RM | 1 |
| Sax, PE | 1 |
| Moyo, S | 1 |
| Stringer, JS | 1 |
| Masheto, G | 1 |
| Korutaro, V | 1 |
| Cassim, H | 1 |
| Mmbaga, BT | 1 |
| João, E | 1 |
| Hanley, S | 1 |
| Purdue, L | 1 |
| Holmes, LB | 1 |
| Momper, JD | 1 |
| Shapiro, RL | 1 |
| Thoofer, NK | 1 |
| Rooney, JF | 1 |
| Frenkel, LM | 1 |
| Amico, KR | 1 |
| Chinula, L | 1 |
| Currier, J | 1 |
| Jorgensen, SCJ | 1 |
| Davis, MR | 1 |
| Lapinsky, SE | 1 |
| Noguera, A | 1 |
| Fortuny, C | 1 |
| Muñoz-Almagro, C | 1 |
| Sanchez, E | 1 |
| Vilaseca, MA | 1 |
| Artuch, R | 1 |
| Pou, J | 1 |
| Jimenez, R | 1 |
| White, NJ | 1 |
| Warrell, DA | 1 |
| Chanthavanich, P | 1 |
| Looareesuwan, S | 1 |
| Warrell, MJ | 1 |
| Krishna, S | 1 |
| Williamson, DH | 1 |
| Turner, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants[NCT03048422] | Phase 3 | 643 participants (Actual) | Interventional | 2018-01-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in maternal antepartum weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline through before delivery (up to one day prior)
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.378 |
| Arm 2: Maternal DTG+FTC/TDF | 0.319 |
| Arm 3: Maternal EFV/FTC/TDF | 0.291 |
Change in maternal weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline to 50 weeks postpartum
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | -0.027 |
| Arm 2: Maternal DTG+FTC/TDF | -0.050 |
| Arm 3: Maternal EFV/FTC/TDF | -0.084 |
Change in maternal postpartum weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Delivery to 50 weeks postpartum
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.014 |
| Arm 2: Maternal DTG+FTC/TDF | -0.008 |
| Arm 3: Maternal EFV/FTC/TDF | -0.032 |
Count of infants with HIV-1 antiretroviral drug resistance mutations (to any antiretroviral drug) at the time of infant HIV diagnosis, based on laboratory blood test results. (NCT03048422)
Timeframe: From birth through 50 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 Infants | 1 |
| Arm 2 Infants | 0 |
| Arm 3 Infants | 1 |
The Kaplan-Meier estimate of the cumulative probability of infant deaths from birth through 50 weeks after birth. (NCT03048422)
Timeframe: Birth through 50 weeks after birth
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 1.0 |
| Arm 2 Infants | 2.0 |
| Arm 3 Infants | 6.9 |
The Kaplan-Meier estimate of the cumulative probability of infants acquiring HIV-1 infection from birth through 50 weeks after birth based on nucleic acid test results. (NCT03048422)
Timeframe: Birth through 50 weeks after birth
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 0.98 |
| Arm 2 Infants | 0.50 |
| Arm 3 Infants | 0.55 |
The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause. (NCT03048422)
Timeframe: Birth through Week 50 postpartum
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arms 1 and 2 Infants | 26.8 |
| Arm 3 Infants | 30.9 |
The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause. (NCT03048422)
Timeframe: From birth through Week 50 postpartum
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 25.3 |
| Arm 2 Infants | 28.6 |
| Arm 3 Infants | 30.9 |
"The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.~Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks." (NCT03048422)
Timeframe: From randomization up to 74 weeks
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 25.1 |
| Arm 2: Maternal DTG+FTC/TDF | 30.8 |
| Arm 3: Maternal EFV/FTC/TDF | 27.9 |
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 27.9 |
| Arm 3: Maternal EFV/FTC/TDF | 27.9 |
Maternal change in creatinine clearance per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline to 50 weeks postpartum
| Intervention | mL/min (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | -0.980 |
| Arm 2: Maternal DTG+FTC/TDF | -0.887 |
| Arm 3: Maternal EFV/FTC/TDF | -0.935 |
Percentage of infants born small for gestational age (<10th percentile adjusted for sex assigned at birth) based on Intergrowth 21st Standards (NCT03048422)
Timeframe: Birth
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 Infants | 16.3 |
| Arm 2 Infants | 22.5 |
| Arm 3 Infants | 20.5 |
Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (<20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (<37 completed weeks), or small for gestational age (<10th percentile by INTERGROWTH 21st Standards) (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 24.1 |
| Arm 2: Maternal DTG+FTC/TDF | 32.9 |
| Arm 3: Maternal EFV/FTC/TDF | 32.7 |
Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (<20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (<37 completed weeks), or small for gestational age (<10th percentile per INTERGROWTH 21st Standards) (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 28.4 |
| Arm 3: Maternal EFV/FTC/TDF | 32.7 |
Percentage of mother-infant pairs with an adverse pregnancy outcome or major congenital anomaly. Adverse pregnancy outcomes include spontaneous abortions (<20 weeks gestation), stillbirths (≥20 weeks gestation), preterm deliveries (<37 weeks gestation), and infants small for gestational age (<10th percentile per INTERGROWTH 21st Standards). Major congenital anomaly was defined consistent with the definition of malformation provided by Holmes and Westgate (i.e., a structural abnormality with surgical, medical, or cosmetic importance) and evaluated by an internal study team blinded to treatment arm. (NCT03048422)
Timeframe: Delivery through 50 weeks postpartum
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 24.1 |
| Arm 2: Maternal DTG+FTC/TDF | 32.9 |
| Arm 3: Maternal EFV/FTC/TDF | 33.2 |
Percentage of mother-infant pairs with preterm deliveries (<37 weeks gestation) resulting in live born infant (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 5.8 |
| Arm 2: Maternal DTG+FTC/TDF | 9.4 |
| Arm 3: Maternal EFV/FTC/TDF | 12.1 |
Percentage of mothers with HIV-1 antiretroviral (ARV) drug resistance mutations at the time of maternal virologic failure. Virologic failure was defined as two consecutive plasma HIV-1 RNA viral loads <200 copies/mL on or after 24 weeks on study. Drug resistance mutations were assessed using the Stanford algorithm, and all ARV regimens were assessed for mutations. (NCT03048422)
Timeframe: From 24 weeks after randomization through Week 50 postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.92 |
| Arm 2: Maternal DTG+FTC/TDF | 1.86 |
| Arm 3: Maternal EFV/FTC/TDF | 6.16 |
Percentage of mothers with HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: 50 weeks postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 96.3 |
| Arm 3: Maternal EFV/FTC/TDF | 96.4 |
Percentage of mothers with HIV-1 RNA less than 50 copies/mL at delivery using batched test results obtained from central laboratory (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 94.4 |
| Arm 3: Maternal EFV/FTC/TDF | 78.8 |
Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum based on FDA snapshot algorithm using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: 50 weeks postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 75.6 |
| Arm 2: Maternal DTG+FTC/TDF | 77.7 |
| Arm 3: Maternal EFV/FTC/TDF | 76.3 |
Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at delivery based on FDA snapshot algorithm using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 88.9 |
| Arm 2: Maternal DTG+FTC/TDF | 92.6 |
| Arm 3: Maternal EFV/FTC/TDF | 81.0 |
Time to first viral HIV-1 RNA less than 200 copies/mL through delivery, determined using real-time results obtained from site laboratories (NCT03048422)
Timeframe: Randomization to delivery
| Intervention | weeks (Mean) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 4.26 |
| Arm 3: Maternal EFV/FTC/TDF | 6.49 |
Infant creatinine clearance based on Schwartz formula (NCT03048422)
Timeframe: Delivery and 26 weeks postpartum
| Intervention | mL/min (Mean) | |
|---|---|---|
| Delivery | 26 Weeks Postpartum | |
| Arm 1 Infants | 52.7 | 134.8 |
| Arm 2 Infants | 53.1 | 123.6 |
| Arm 3 Infants | 49.0 | 135.0 |
Percentage of mothers with plasma HIV-1 RNA viral load less than 200 copies/mL at delivery determined using real-time test results obtained at site laboratories. This outcome was evaluated in the non-inferiority (primary outcome) and superiority (secondary outcome) analyses. The intention-to-treat analysis included all randomized women who had viral load data available. The per-protocol analysis excluded women who modified randomized treatment (stopped, paused, switched, added any treatment) before viral load evaluation at delivery, with the exception of women who modified randomized treatment for use of a concomitant medication. (NCT03048422)
Timeframe: Delivery
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Intention-to-Treat Analysis | Per-Protocol Analysis | |
| Arm 3: Maternal EFV/FTC/TDF | 91.0 | 91.4 |
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 97.5 | 97.5 |
2 reviews available for alanine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Lactation; Pregnancy; Pregnancy C | 2020 |
A review of remdesivir for COVID-19 in pregnancy and lactation.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Breast Feeding; COVID-19 Drug Treatment; Female; | 2021 |
1 trial available for alanine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestatio | 2021 |
14 other studies available for alanine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Early Administration of Remdesivir and Intensive Care Unit Admission in Hospitalized Pregnant Individuals With Coronavirus Disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Intensiv | 2022 |
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Female; HIV Infections; Humans; Postpart | 2022 |
Remdesivir impairs mouse preimplantation embryo development at therapeutic concentrations.
Topics: Adenosine Monophosphate; Alanine; Animals; Blastocyst; COVID-19 Drug Treatment; Embryonic Developmen | 2022 |
Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Adult; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betaco | 2020 |
Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; Female; | 2020 |
Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Clinical Decision-Making; Compassionate U | 2020 |
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
Topics: Abnormalities, Drug-Induced; Adenine; Adult; Alanine; Chemoprevention; China; Cohort Studies; DNA, V | 2020 |
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adult; Alanine; Compassionate Use Trials; COVID-19 Drug Treatment; Female; | 2021 |
Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Congenital Abnormalities; COVID-1 | 2020 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newbor | 2021 |
Remdesivir (Veklury) for COVID-19.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19 Drug T | 2020 |
Remdesivir for the treatment of COVID-19 in pregnancy.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; COVID-19 Drug Treatment; Female; Humans; | 2021 |
Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.
Topics: Alanine; Antiretroviral Therapy, Highly Active; Didanosine; Female; HIV Infections; HIV Seronegativi | 2004 |
Severe hypoglycemia and hyperinsulinemia in falciparum malaria.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Alanine; Blood Glucose; Brain Diseases; C-Peptide; Child; | 1983 |